$CYDY CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications.
#CYDY
Annual shareholders meeting update.
https://www.cytodyn.com/newsroom/press-releas...meeting-of